Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis
In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been shown to be effective and safe in several studies. Their side effects are...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2021-07-01
|
| Series: | Case Reports in Dermatology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/513467 |